OCUMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUMYCIN (OCUMYCIN).
Ocimycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
| Metabolism | Primarily hepatic via CYP3A4; metabolite is active. |
| Excretion | Renal excretion accounts for 60-70% of elimination as unchanged drug, with 10-15% as inactive metabolites; biliary/fecal excretion contributes 20-30%, with enterohepatic recirculation noted. |
| Half-life | Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 80-90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 0.8-1.2 L/kg, indicating extensive tissue penetration (not restricted to extracellular fluid). |
| Bioavailability | Oral: 70-80% (high first-pass metabolism reduces systemic exposure; food decreases absorption by 20%). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes (peak effect at 1-2 hours); Topical ophthalmic: 15-30 minutes. |
| Duration of Action | Oral/IV: 12-24 hours depending on dose; Topical ophthalmic: 4-6 hours. |
1-2 drops in affected eye(s) every 4 hours while awake, increasing to every 2 hours for severe infection. Ophthalmic ointment: 0.5-inch ribbon into conjunctival sac 2-4 times daily.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical ocular use due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for topical ocular use due to minimal systemic absorption. |
| Pediatric use | Same as adult dosing: 1-2 drops in affected eye(s) every 4 hours while awake, or 0.5-inch ribbon of ointment 2-4 times daily. Weight-based adjustments not necessary for topical ophthalmic use. |
| Geriatric use | No specific dose adjustment required; use same dosing as younger adults. Monitor for local adverse effects due to potential age-related ocular surface changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OCUMYCIN (OCUMYCIN).
| Breastfeeding | Excreted in breast milk in low concentrations; M/P ratio unknown. Use with caution due to risk of infant gut flora alteration and theoretical ototoxicity/nephrotoxicity. Consider alternative if possible. |
| Teratogenic Risk | First trimester: No adequate human studies; animal studies show embryotoxicity at high doses. Second and third trimesters: Potential for ototoxicity and nephrotoxicity in fetus; avoid unless essential. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to ocimycin or other macrolides; concurrent use with pimozide or ergot alkaloids.
| Precautions | Prolonged use may lead to C. difficile-associated diarrhea; hepatotoxicity reported; monitor liver enzymes. |
Loading safety data…
| Monitor maternal renal function, hearing (audiometry), and fetal growth via ultrasound. Assess for signs of fetal distress if used near term. |
| Fertility Effects | No known impact on fertility in humans; animal studies show no reproductive impairment at therapeutic doses. |